Article Type : Research Article
Authors : Benitez Herrera A and López Rodríguez PR
Keywords : Implant; Stem cells; Regenerative medicine
Introduction: Since the beginning of the last century,
multiple investigations have been carried out in the field of Regenerative
Medicine. Stem cells obtained by different routes have been implanted in
different injured tissue in order to achieve its regeneration.
Objective: To demonstrate the feasibility and safety
of the implantation of autologous MO-CMA by subarachnoid puncture.
Method: A study is carried out by implanting
autologous stem cells by subarachnoid puncture in five patients who had
undergone a first open implant due to a neurological lesion of traumatic
etiology. January 2016 to December 2018, at the Enrique Cabrera General
Teaching Hospital.
Results: The second implant was completed in 5
patients and the following advantages were obtained: less surgical time, less
possibility of sepsis, no blood loss, less hospital stay and fewer
complications.
Conclusions: The feasibility and safety of stem cell
implantation by subarachnoid puncture without complications is demonstrated in
this study.
In recent years there has
been an extraordinary advance in knowledge related to different biomedical
branches, including cell biology. This has given a remarkable boost to a new
branch of medicine called regenerative medicine, which has been considered a
"New Revolution in Medicine". This medical discipline has been based
primarily on new knowledge about stem cells and their ability to become cells
of different tissues and whose objective is to stimulate or regenerate cells,
tissues or organs in order to restore or establish normal function [1-5].
Methods
We have carried out a
descriptive observational cross-sectional study in thirty patients with a first
open implant of autologous adult stem cells obtained from bone marrow (ACM-MO)
in patients with chronic spinal cord injury of traumatic etiology with
encouraging results. We have recently practiced a second implant in 5 cases of
stem cells by subarachnoid puncture, from January 2016 to 2018 at the Enrique
Cabrera General Teaching Hospital.
Description of the
Technique
The patient is admitted
with the corresponding investigations and approval for anesthesia, two days
before the implant, stimulation with leukocin (growth factor of granulocyte
colonies) begins at a rate of 5 mg / kg of weights every 12 hours until 4 doses
are applied. Stem cells are obtained from peripheral blood by the
centrifugation method in the laboratory. In the operating room in a sitting
position, after washing the area with soap and water, antisepsis is performed
with iodinated alcohol, field cloths are placed and the intervertebral space
corresponding to the spinal cord injury is located, skin wheal is performed
with lidocaine 1 % and then it infiltrates deeper planes. Following the
anterior scar and under radiographic control, a subarachnoid puncture with
trocar # 22 is performed above and below the lesion, implanting 5cc stem cells
in each intervertebral space, confirming the location of the space with the
previous aspiration of cerebrospinal fluid. Trocar and the rest of stem cells
are administered by IV route in 100cc of physiological saline for 30 minutes.
Results
Patient relationship:
In all cases it has been
possible to carry out the procedure without great difficulties and there have
been no complications.
Discussion
Regenerative Medicine is
based on the potential of stem cells to become cells of different tissues [6-10].
Autologous adult stem cells used to treat spinal cord injury patients have
several advantages.
First:
Problems associated with immune rejection or graft-versus-host reactions can be
avoided [11-13].
Second:
CMA-MO transplantation is considered a safe method since its association with
carcinogenesis has not been reported [14,15].
Third:
There is great experience with the use of transplantation of these cells in
hematological diseases [16].
Conclusions
The feasibility and
safety of stem cell implantation by subarachnoid puncture is demonstrated. None
of our cases have presented complications that could put this technique at
risk.
Conflicts of Interest
The authors do not
declare any conflicts of interest.
Authors' contributions
Alberto Benitez Herrera: he reviewed the literature on the subject looking for
epidemiological data worldwide, designed the study methodology, classified the
research, processed the information and limited the bibliographic references
according to Vancouver standards. He wrote the document.
Pedro Rolando López Rodríguez: he declared the objectives of the study,
selected and triangulated the variables and carried out the translation into
English and the final revision of the manuscript. He performed the statistical
processing. He contributed to the preparation of the article.
1.
Okubo
T, Iwanami A, Kohyama J. Pretreatment with a gammasecretase inhibitor prevents
tumor-like overgrowth in human iPSC derived transplants for spinal cord injury.
Stem Cell Reports. 2016; 7: 649-663.
2.
Fujimoto
Y, Abematsu M, Falk A. Treatment of a mouse model of spinal cord injury by
transplantation of human induced pluripotent stem cell-derived long-term
self-renewing neuroepithelial-like stem cells. Stem Cells. 2012; 30: 1163-1173.
3.
Romanyuk
N, Amemori T, Turnovcova K. Beneficial effect ofhuman induced pluripotent stem
cell-derived neural precursors in spinalcord injury repair. Cell Transplant.
2015; 24: 1781-1797.
4.
Enomoto
M. Therapeutic effects of neurotrophic factors in experimentalspinal cord
injury models. J Neurorestoratol. 2016; 4: 15-22.
5.
Fuhrmann
T, Anandakumaran PN, Shoichet MS. Combinatorial therapies after spinal cord
injury: how can biomaterials help? Adv HealthcMater. 2017.
6.
Raspa
A, Pugliese R, Maleki M, Gelain F. Recent therapeutic approaches for spinal
cord injury. Biotechnol Bioeng. 2016; 113: 253-259.
7.
Slotkin
JR, Pritchard CD, Luque B. Biodegradable scaffolds promote tissue remodeling
and functional improvement in non-human primates with acute spinal cord injury.
Biomaterials. 2017; 123: 63-76.
8.
Li
X, Zhao Y, Cheng S. Cetuximab modified collagen scaffold directs neurogenesis
of injury-activated endogenous neural stem cells for acute spinal cord injury
repair. Biomaterials. 2017; 137: 73-86.
9.
Iyer
NR, Wilems TS, Sakiyama-Elbert SE. Stem cells for spinal cordinjury: strategies
to inform differentiation and transplantation. Biotechnol Bioeng. 2017; 114:
245-259.
10.
Chen
C, Zhao ML, Zhang RK. Collagen / heparin sulfate scaffoldsfabricated by a 3D
bioprinter improved mechanical properties and neurological function after
spinal cord injury in rats. J Biomed Mater Res A. 2017; 105: 1324-1332.
11.
Nejati-Koshki
K, Mortazavi Y, Pilehvar-Soltanahmadi Y, Sheoran S, Zarghami N. An update on
application of nanotechnology andstem cells in spinal cord injury regeneration.
Biomed Pharmacother. 2017; 90: 85-92.
12.
Nagoshi
N, Okano H. Applications of induced pluripotent stem celltechnologies in spinal
cord injury. J Neurochem. 2017.
13.
Karimi-Abdolrezaee
S, Schut D, Wang J, Fehlings MG. Chondroitinase and growth factors enhance
activation and oligodendrocyte differentiation of endogenous neural precursor
cells after spinal cord injury. PLoS One. 2012; 7: e37589.
14.
Kaneko
S, Iwanami A, Nakamura M. A selective Sema3A inhibitor enhances regenerative
responses and functional recovery of the injured spinal cord. Nat Med. 2006;
12: 1380-1389.
15.
US
Food & Drug Administration. Vaccines, Blood & Biologics.
16.
Hernández
Ramírez Q. Is treatment with regenerative cell therapy really useful? Rev
Cubana Hematol Inmunol Hemoter. 2017; 33.